title: Efficacy and safety of phosphodiesterase-5 inhibitors for treating erectile dysfunction in kidney transplant recipients: a meta-analysis.
abstract: OBJECTIVE
  Erectile dysfunction is common after kidney transplant. The phosphodiesterase-5 inhibitors are the primary drugs for the treatment of erectile dysfunction. The purpose of this study was to evaluate the efficacy and safety of these drugs in the treatment of erectile dysfunction after kidney transplant.
  
  
  METHODS
  Randomized controlled trials were identified and extracted from MEDLINE, the Web of Science, Cochrane Central, and reference lists. The database search, quality assessment, and data extraction were performed independently by 2 reviewers. Eligible studies were randomized controlled trials and quasi-randomized controlled trials. Treatment efficacy was assessed with the International Index of Erectile Function score.
  
  
  RESULTS
  There were 3 studies identified that satisfied inclusion criteria. The International Index of Erectile Function score for phosphodiesterase-5 inhibitors increased ≥ 9 points compared with placebo (mean difference, 11.81; 95% confidence interval: 9.14-14.48; P < .00001). There were no differences between the phosphodiesterase-5 inhibitors and placebo in the incidence of adverse events, creatinine levels, or concentrations of cyclosporine or tacrolimus.
  
  
  CONCLUSIONS
  Phosphodiesterase-5 inhibitors are effective and safe in treating erectile dysfunction after kidney transplant. Phosphodiesterase-5 inhibitors do not cause changes in kidney function or immunosuppressive drug concentrations after kidney transplant and may be used as the first-line treatment for erectile dysfunction in kidney transplant recipients.
authors.affiliation: First Affiliated Hospital of Wenzhou Medical College, Organ Transplantation Center, Wenzhou, Zhejiang, China.
authors.forename: Lv
authors.initials: L
authors.lastname: Fanbin
authors.forename: Yang
authors.initials: Y
authors.lastname: Mei
authors.forename: Zhang
authors.initials: Z
authors.lastname: Yan
authors.forename: Yang
authors.initials: Y
authors.lastname: Yirong
authors.forename: Zheng
authors.initials: Z
authors.lastname: Shaoling
authors.forename: Cai
authors.initials: C
authors.lastname: Yong
authors.forename: Xia
authors.initials: X
authors.lastname: Peng
mesh_terms: D016009:Chi-Square Distribution; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D016017:Odds Ratio; D010410:Penile Erection / Q000187:drug effects*; D058986:Phosphodiesterase 5 Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D020127:Recovery of Function; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D058986:Phosphodiesterase 5 Inhibitors